Get started
Author

John C. LaMacchia

Observed names: J.C. Lamacchia, John C LaMacchia, John LaMacchia, John Lamacchia
OpenAlex ID: A5076290544
A Rapid Dilute-and-Shoot UPLC-MS/MS Assay to Simultaneously Measure 37 Drugs and Related Metabolites in Human Urine for Use in Clinical Pain Management
2019 · Jayme L Dahlin, Michael J Palte, et al. · The Journal of Applied Laboratory Medicine · 27
Glycogen Fuels Survival During Hyposmotic-Anoxic Stress in Caenorhabditis elegans
2015 · John C LaMacchia, Harold N Frazier, et al. · Genetics · 25
Complete response to pembrolizumab and radiation in a patient with HIV ‐negative, EBV ‐positive plasmablastic lymphoma
2021 · Jorge J. Castillo, John Lamacchia, et al. · American Journal of Hematology · 14
PDF
Aquaporins-2 and - 4 regulate glycogen metabolism and survival during hyposmotic-anoxic stress in Caenorhabditis elegans
2015 · John C. LaMacchia, Mark B. Roth · American Journal of Physiology-Cell Physiology · 14
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
2024 · Attaya Suvannasankha, Nizar Bahlis, et al. · Cancer · 11
MiSet RFC Standards: Defining a Universal Minimum Set of Standards Required for Reproducibility and Rigor in Research Flow Cytometry Experiments
2019 · Fabienne Lucas, Jesus Gil‐Pulido, et al. · Cytometry Part A · 11
PDF
P913: Low-dose Belantamab Mafodotin (belamaf) in Combination With Nirogacestat Vs Belamaf Monotherapy in Patients With Relapsed/refractory Multiple Myeloma (rrmm): Phase 1/2 Dreamm-5 Platform Sub-study 3
2023 · Natalie Callander, Paul Richardson, et al. · HemaSphere · 5
A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.
2025 · Wasif M. Saif, Philippe Alexandre Cassier, et al. · Journal of Clinical Oncology · 4
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib
2021 · Jorge J. Castillo, John LaMacchia, et al. · British Journal of Haematology · 4
PDF
345TiP: A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homologue 3 (B7-H3) protein-targeted antibody-drug conjugate (ADC), in combination with standard of care (SoC), in patients with advanced solid tumours, including lung cancers
2025 · H.R. Kim, P. Cassier, et al. · Journal of Thoracic Oncology · 1
PDF
Abstract CT195: A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors
2025 · Hye Ryun Kim, Philippe Cassier, et al. · Cancer Research
168TiP A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
2024 · G. Curigliano, P. Cassier, et al. · Immuno-Oncology Technology
PDF
MM-533 Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
2023 · Natalie S. Callander, Paul G. Richardson, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-533 Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
2023 · Natalie S. Callander, Paul G. Richardson, et al. · Clinical Lymphoma Myeloma & Leukemia
How FLT3-ITDs and NPM1 Insertions Maneuver Into AML Using the Lymphoid Enzyme TdT to Initiate Replication Slippage
2020 · Annette S. Kim, John C. LaMacchia · The Hematologist
ADAPTATION AND SURVIVAL OF THE NEMATODE Caenorhabditis elegans DURING OSMOTIC-ANOXIC STRESS
2015 · John LaMacchia · ResearchWorks at the University of Washington (University of Washington)
PDF
Works count: 16
Citation count: 116
H-index: 6
I10-index: 6
Year
Topic
Type